Abstract
Angiogenesis is the fundamental process by which new blood vessels are formed. Extensive research has shown that this event can be co-opted by tumors to ensure their growth, survival and metastasis. The study of tumor angiogenesis therefore represents a promising area of research for development of anti-cancer therapeutics. Integrins, a family of cell surface molecules, are a major target of interest as they are known to play a vital role in pathological angiogenesis. Remarkably, small disulfide-rich peptides known as disintegrins, isolated from the venoms of various snake species have been found to bind integrins with extremely high affinity and block their function. Disintegrins are capable of inhibiting several aspects of tumor cell behavior both in vitro and in vivo, including adhesion, migration, invasion, metastasis and angiogenesis. In this review, we will briefly discuss tumor angiogenesis and molecules implicated in the angiogenic process, with a special focus on the role of integrins. We will also discuss therapeutic approaches towards the treatment of tumor angiogenesis, including non-integrin-targeted agents currently in clinical trials. We will summarize the major findings from studies using disintegrins to target integrin-associated angiogenesis in cancer models. Finally, we will present results obtained in our laboratory using the novel dimeric disintegrin, contortrostatin (CN), in studies of endothelial cells and models of breast, ovarian and prostate cancer. In summary, disintegrins represent an exciting new class of molecules that can potentially be used in a clinical setting to inhibit angiogenesis and augment conventional chemotherapeutic agents in the treatment of cancer.
Keywords: vascular endothelial growth factor, Anti-angiogenic therapy, tumor progression, contortrostatin, human umbilical vein endothelial cells
Current Pharmaceutical Design
Title: Anti-Angiogenesis and RGD-Containing Snake Venom Disintegrins
Volume: 13 Issue: 28
Author(s): Stephen Swenson, Swapnika Ramu and Francis S. Markland
Affiliation:
Keywords: vascular endothelial growth factor, Anti-angiogenic therapy, tumor progression, contortrostatin, human umbilical vein endothelial cells
Abstract: Angiogenesis is the fundamental process by which new blood vessels are formed. Extensive research has shown that this event can be co-opted by tumors to ensure their growth, survival and metastasis. The study of tumor angiogenesis therefore represents a promising area of research for development of anti-cancer therapeutics. Integrins, a family of cell surface molecules, are a major target of interest as they are known to play a vital role in pathological angiogenesis. Remarkably, small disulfide-rich peptides known as disintegrins, isolated from the venoms of various snake species have been found to bind integrins with extremely high affinity and block their function. Disintegrins are capable of inhibiting several aspects of tumor cell behavior both in vitro and in vivo, including adhesion, migration, invasion, metastasis and angiogenesis. In this review, we will briefly discuss tumor angiogenesis and molecules implicated in the angiogenic process, with a special focus on the role of integrins. We will also discuss therapeutic approaches towards the treatment of tumor angiogenesis, including non-integrin-targeted agents currently in clinical trials. We will summarize the major findings from studies using disintegrins to target integrin-associated angiogenesis in cancer models. Finally, we will present results obtained in our laboratory using the novel dimeric disintegrin, contortrostatin (CN), in studies of endothelial cells and models of breast, ovarian and prostate cancer. In summary, disintegrins represent an exciting new class of molecules that can potentially be used in a clinical setting to inhibit angiogenesis and augment conventional chemotherapeutic agents in the treatment of cancer.
Export Options
About this article
Cite this article as:
Swenson Stephen, Ramu Swapnika and Markland S. Francis, Anti-Angiogenesis and RGD-Containing Snake Venom Disintegrins, Current Pharmaceutical Design 2007; 13 (28) . https://dx.doi.org/10.2174/138161207782023793
DOI https://dx.doi.org/10.2174/138161207782023793 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tissue Elastography: Advances in Imaging the Mechanical Properties of Tissue
Recent Patents on Electrical Engineering Photoprotective Carotenoids Lutein and Zeaxanthin: Their Role in AMD
Current Nutrition & Food Science Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Regulation of Radiation-Induced Apoptosis by Early Growth Response-1 Gene in Solid Tumors
Current Cancer Drug Targets Editorial (Hot Topic: Pharmacological and Molecular Targets in Cellular Redox Status Maintenance)
Current Pharmaceutical Design HIV-Therapy Associated Lipodystrophy: Experimental and Clinical Evidence for the Pathogenesis and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis of Mannich Bases by Two Different Methods and Evaluation of their Acetylcholine Esterase and Carbonic Anhydrase Inhibitory Activities
Letters in Drug Design & Discovery Synthesis and Evaluation of Glycyrrhetic Acid-aromatic Hybrids as Anti-inflammatory Agents
Medicinal Chemistry Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations
Current Rheumatology Reviews Approach to the Patient with Subclinical Cushing’s Syndrome
Current Pharmaceutical Design Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Toxicity of Magnetic Resonance Imaging Agents: Small Molecule and Nanoparticle
Current Topics in Medicinal Chemistry Epigenetic Metalloenzymes
Current Medicinal Chemistry Discovery and Hit to Lead Optimization of Novel Combretastatin A-4 Analogues: Dependence of C-Linker Length and Hybridization
Anti-Cancer Agents in Medicinal Chemistry Thrombospondins as Anti-Angiogenic Therapeutic Agents
Current Pharmaceutical Design Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Editorial (Thematic Issue: Cancer Biomarkers from Bench to Bedside)
Current Cancer Drug Targets Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine Seeking the 5th Base of DNA Using Chromatographic Methods of Analysis
Current Organic Chemistry The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia
Current Medicinal Chemistry